To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage

Phase 1 Recruiting 24 enrolled Ganzhou Hemay Pharmaceutical Co., Ltd

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the pharmacokinetics of Hemay 005 tablets in subjects with mild, moderate liver impairment and normal liver function, and to provide a basis for the formulation of clinical medication regimens for patients with liver impairment.

Timeline

Start: 2024-04-28
Primary completion: 2025-12-10
Completion: 2025-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MUFEMILAST	Small molecule	60 mg	Oral

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage

Summary

Timeline

Drugs

Indications